Latest Commercialisation Strategy News

Echo IQ has secured a strategic collaboration with the Mayo Clinic Platform and raised $17.3 million, advancing its AI-driven cardiology tools towards FDA clearance and US commercial scale.

Sunshine Metals has launched an advanced scoping study targeting 95,000 ounces of gold and 652,000 ounces of silver at its Liontown project in North Queensland. The study aims to optimise extraction from multiple high-grade resource domains, with metallurgical test results expected in August 2025.

Amaero Ltd reports solid June quarter revenue and signs a pivotal five-year exclusive supply agreement with Velo3D, underpinning its growth outlook and updated EBITDA guidance for FY2027.

Metallium Ltd has completed a A$50 million institutional raise, secured a Texas site, and validated its commercial Flash Joule Heating reactor, setting the stage for its first U.S. metals recovery plant commissioning by year-end 2025.

ImpediMed has doubled its US unit sales in Q4 FY25, achieving a record total contract value and securing an additional $5 million tranche under its growth capital facility.

Archer Materials advances its quantum computing and medical diagnostics technologies, extending key partnerships and forming a new advisory board while maintaining a strong cash position to fuel development.

InteliCare has launched a three-month trial of its AI-powered platform at mecwacare’s Trescowthick Centre, marking a significant step in its commercialisation strategy with a leading aged care provider.

Echo IQ has secured a pivotal reseller agreement with US-based SARC MedIQ, unlocking access to over 300 healthcare facilities and accelerating adoption of its AI-driven EchoSolv AS technology across the American cardiology landscape.

Orthocell Limited has posted a record quarterly revenue of A$2.73 million, driven by strong Australian sales of its nerve repair product Remplir™, with US market expansion poised to accelerate in FY26.

First Graphene Limited has secured two significant orders totaling approximately A$165,000 for its PureGRAPH graphene products, signaling growing market acceptance and supporting its FY25-26 sales outlook.

Astral Resources has released a compelling Pre-Feasibility Study for its Mandilla Gold Project in Western Australia, outlining a 19-year mine life with robust economics and a maiden ore reserve of 1.1 million ounces. The study sets the stage for a Definitive Feasibility Study targeted for mid-2026.

Rhythm Biosciences has regained NATA accreditation for its geneType laboratory, a key step toward commercialising its ColoSTAT® cancer risk test as an in-house diagnostic.